We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.

Delisted

AVEO was delisted on the 19th of January, 2023.

49 hedge funds and large institutions have $22.5M invested in AVEO Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 6 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 6

78% more capital invested

Capital invested by funds: $12.6M → $22.5M (+$9.83M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

4% less funds holding

Funds holding: 5149 (-2)

18% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 11

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $116K

Holders
49
Holders Change
-2
Holders Change %
-3.92%
% of All Funds
1.31%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
9
Increased
17
Reduced
6
Closed
11
Calls
Puts
$116K
Net Calls
-$116K
Net Calls Change
-$38K
Name Holding Trade Value Shares
Change
Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
26
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$104K +$18.2K +1,670 +30%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$96K
NCCM
28
Nine Chapters Capital Management
New Jersey
$94K +$71K +6,500 New
RFC
29
Russell Frank Company
Washington
$93K +$70.2K +6,425 New
CCMH
30
Cornerstone Capital Management Holdings
New York
$73K
Morgan Stanley
31
Morgan Stanley
New York
$72K +$41.4K +3,789 +306%
TC
32
TFS Capital
Pennsylvania
$64K +$48.3K +4,418 New
EWM
33
Evercore Wealth Management
New York
$56K +$8.11K +742 +24%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$50K -$886K -81,094 -96%
State Street
35
State Street
Massachusetts
$36K
Charles Schwab
36
Charles Schwab
California
$22K
FMA
37
FNY Managed Accounts
New York
$18.1K +$13.7K +1,250 New
RMCM
38
Reynders McVeigh Capital Management
Massachusetts
$18K +$13.8K +1,260 New
GC
39
Guggenheim Capital
Illinois
$17K +$1.58K +145 +14%
EWM
40
Edge Wealth Management
New York
$14K
BIM
41
BlackRock Investment Management
Delaware
$12K
Group One Trading
42
Group One Trading
Illinois
$11K -$10.1K -926 -55%
UBS Group
43
UBS Group
Switzerland
$4K -$31.4K -2,873 -90%
BWA
44
Burt Wealth Advisors
Maryland
$2K
CFA
45
CT Financial Advisors
Pennsylvania
$1.16K
AIG
46
American International Group
New York
$1K
GC
47
Globeflex Capital
California
$1K -$273 -25 -27%
Wells Fargo
48
Wells Fargo
California
$1K
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2
PAI
50
Palo Alto Investors
California
-$562K -66,945 Closed

AVEO Hedge Fund Activity: Q1 2015 in Review

49 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2015, worth a combined $22.5M — up 78% from $12.6M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of AVEO and 9 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 17 added.

The largest buyer was Renaissance Technologies, adding an estimated $656K. The largest seller was D.E. Shaw & Co, cutting an estimated $886K.

  • 49 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2015, down from 51 in Q4 2014.
  • Funds reported $22.5M of AVEO Pharmaceuticals, Inc. stock for Q1 2015, up 78% quarter-over-quarter.
  • 9 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2015 and 11 closed out, a net change of -2 holders.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q1 2015 was Renaissance Technologies, an estimated $656K added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q1 2015 was D.E. Shaw & Co, an estimated $886K sold.

Based on aggregated 13F filings for Q1 2015.